Plasma Protein Binding of Amphotericin B and Pharmacokinetics of Bound versus Unbound Amphotericin B after Administration of Intravenous Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate

Abstract

Unilamellar liposomal amphotericin B (AmBisome) (liposomal AMB) reduces the toxicity of this antifungal drug. The unique composition of liposomal AMB stabilizes the liposomes, producing higher sustained drug levels in plasma and reducing renal and hepatic excretion. When liposomes release their drug payload, unbound, protein-bound, and liposomal drug pools may exist simultaneously in the body. To determine the amounts of drug in these pools, we developed a procedure to measure unbound AMB in human plasma by ultrafiltration and then used it to characterize AMB binding in vitro and to assess the pharmacokinetics of nonliposomal pools of AMB in a phase IV study of liposomal AMB and AMB deoxycholate in healthy subjects. We confirmed that AMB is highly bound (>95%) in human plasma and showed that both human serum albumin and ␣ 1 -acid glycoprotein contribute to this binding. AMB binding exhibited an unusual concentration dependence in plasma: the percentage of bound drug increased as the AMB concentration increased. This was attributed to the low solubility of AMB in plasma, which limits the unbound drug concentration to <1 g/ml. Subjects given 2 mg of liposomal AMB/kg of body weight had lower exposures (as measured by the maximum concentration of drug in serum and the area under the concentration-time curve) to both unbound and nonliposomal drug than those receiving 0.6 mg of AMB deoxycholate/kg. Most of the AMB in plasma remained liposome associated (97% at 4 h, 55% at 168 h) after liposomal AMB administration, so that unbound drug concentrations remained at <25 ng/ml in all liposomal AMB-treated subjects. Although liposomal AMB markedly reduces the total urinary and fecal recoveries of AMB, urinary and fecal clearances based on unbound AMB were similar (94 to 121 ml h ؊1 kg ؊1 ) for both formulations. Unbound drug urinary clearances were equal to the glomerular filtration rate, and tubular transit rates were <16% of the urinary excretion rate, suggesting that net filtration of unbound drug, with little secretion or reabsorption, is the mechanism of renal clearance for both conventional and liposomal AMB in humans. Unbound drug fecal clearances were also similar for the two formulations. Thus, liposomal AMB increases total AMB concentrations while decreasing unbound AMB concentrations in plasma as a result of sequestration of the drug in long-circulating liposomes.Recent advances in drug delivery technology have resulted in the development of lipid-based formulations of amphotericin B, an effective but toxic fungicidal drug used in the treatment of invasive fungal infections (4). Liposomal amphotericin B (AmBisome), a liposomal formulation of amphotericin B in small, unilamellar vesicles, is significantly less toxic than the conventional amphotericin B deoxycholate formulation (5,11,26) and is currently indicated for the treatment of disseminated fungal infections and visceral leishmaniasis and as empirical therapy for persistent febrile neutropenia. The unique therapeutic properties of liposomal amphotericin B hav...

Direct Comparison of the Pharmacodynamics of Four Antifungal Drugs in a Mouse Model of Disseminated Candidiasis Using Microbiological Assays of Serum Drug Concentrations

“…Table 1 shows the in vitro activities of the antifungal drugs against C. albicans ATCC90028, as determined in mouse serum (mMIC for the azole drugs or MIC for amphotericin B) or by the modified CLSI protocol. Differences between MICs of the two methods did not correlate with measures of rates of protein binding (8,21) which meet with general acceptance.…”

Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics

“…Amphotericin B is extensively protein bound in serum to lipoproteins via cholesterol, 30 serum albumin and human a1-acid glycoprotein, 31 but liposomal amphotericin largely remains within the liposomes in serum and hence does not appear to be significantly protein bound (Table 3). 31 The metabolic pathway of amphotericin B and liposomal amphotericin is largely unknown, 28,32 rendering assessment of the impact of genetic variation somewhat speculative. In the case of amphotericin B deoxycholate, most of the drug is excreted unchanged in urine or faeces with 490% recovered within 7 days, suggesting that little metabolic breakdown occurs.…”

In Vitro Antifungal Activity of Cysteine Derivatives and their Combinations with Antifungal Agents Against Clinically Relevant Scedosporium species

“…In combination with LCME, the MIC ranges of AMB, CSP, TRB, and VRC were decreased to 0.25 -4 µg/ml, 0.125 -16 µg/ml, 4 -8 µg/ml, and 0.125 -4 µg/ml, respectively (Table 3). Compared to the single use, the MIC values of antifungal drugs in the combination tests could be decreased to their achievable therapeutic plasma concentrations in several cases [18][19][20][21].…”